期刊
EXPERT REVIEW OF RESPIRATORY MEDICINE
卷 5, 期 3, 页码 315-328出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERS.11.38
关键词
cGMP; natriuretic peptide; nitric oxide; phosphodiesterase inhibitor; phosphodiesterase type-5; primary pulmonary hypertension; pulmonary arterial hypertension; pulmonary hypertension treatment; tadalafil
资金
- Actelion
- Bayer
- Gilead
- Pfizer
- United Therapeutics
Expert Rev. Respir. Med. 5(3), 315-328 (2011) Tadalafil is a selective inhibitor of phosphodiesterase type-5 (PDE-5) that was originally developed for the treatment of male erectile dysfunction and recently approved for the treatment of pulmonary arterial hypertension (PAH). The antipulmonary hypertensive effects of nitric oxide and the natriuretic peptides are mediated via increasing intracellular cGMP and enzymatic degradation by PDE-5 is the major route of cGMP inactivation in the lung. Evidence is accruing that PDE-5 activity is increased in pulmonary vascular diseases and may contribute to the pathogenesis of PAH. The longer half-life of tadalafil allows for once-daily dosing as compared with three-times daily dosing for sildenafil, the only other PDE-5 inhibitor currently approved for treatment of PAH. This article reviews the role of cGMP and PDE-5 in PAH, presents the results of recent clinical trials and discusses the role of tadalafil in the treatment of this rare but difficult-to-treat disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据